Somewhat Favorable News Coverage Somewhat Unlikely to Affect Evolent Health (EVH) Stock Price
Media headlines about Evolent Health (NYSE:EVH) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Evolent Health earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media stories about the technology company an impact score of 45.6058247792394 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern’s analysis:
- Evolent Health Inc Class A Com (EVH) Receives $29.75 Average Price Target – ExpertGazette (expertgazette.com)
- SunTrust Banks Comments on Evolent Health, Inc’s FY2017 Earnings (EVH) (americanbankingnews.com)
- SunTrust Banks Equities Analysts Cut Earnings Estimates for Evolent Health, Inc (EVH) (americanbankingnews.com)
- Evolent Health, Inc. (EVH) noted a price change of -4.86% and Inseego Corp. (INSG) closes with a move of 0.77% – Stocks Gallery (stocksgallery.com)
- Evolent Health, Inc (EVH) Stock Rating Reaffirmed by SunTrust Banks, Inc. (americanbankingnews.com)
Shares of Evolent Health (NYSE:EVH) traded up 3.40% during mid-day trading on Friday, reaching $16.75. 1,852,583 shares of the company’s stock traded hands. Evolent Health has a 12-month low of $14.50 and a 12-month high of $25.66. The company’s market cap is $1.10 billion. The firm has a 50-day moving average of $17.19 and a 200 day moving average of $17.19.
Evolent Health (NYSE:EVH) last issued its earnings results on Monday, August 7th. The technology company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13). The firm had revenue of $107.30 million during the quarter, compared to analyst estimates of $104.45 million. Evolent Health had a negative net margin of 17.57% and a negative return on equity of 6.44%. The company’s quarterly revenue was up 89.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.20) earnings per share. Equities analysts forecast that Evolent Health will post ($0.41) EPS for the current year.
Several brokerages recently commented on EVH. BidaskClub raised shares of Evolent Health from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 13th. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Evolent Health in a report on Friday, August 18th. Leerink Swann reaffirmed an “outperform” rating and set a $32.00 target price (up previously from $30.00) on shares of Evolent Health in a report on Monday, June 19th. Robert W. Baird set a $35.00 target price on shares of Evolent Health and gave the stock a “buy” rating in a report on Tuesday, August 8th. Finally, SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $30.00 target price on shares of Evolent Health in a report on Wednesday. Three analysts have rated the stock with a sell rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $29.33.
In other Evolent Health news, insider Tpg Growth Ii Advisors, Inc. sold 4,279,325 shares of the stock in a transaction dated Wednesday, June 28th. The shares were sold at an average price of $25.87, for a total transaction of $110,706,137.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Frank J. Williams sold 16,300 shares of the stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $23.73, for a total transaction of $386,799.00. The disclosure for this sale can be found here. Insiders have sold 4,366,132 shares of company stock valued at $112,891,200 in the last quarter. Company insiders own 8.79% of the company’s stock.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Stock Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related stocks with our FREE daily email newsletter.